Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 299 results for "dr reddy"

Market Update: Tech Mahindra, Dr Reddy#39;s top gainers, Tata Comm up 4%; TCS, Maruti most active
Money Control

Dr Reddys Laboratories Ltd is up for a third straight session ...

e stock is quoting at Rs 2223.65, up 1.36% on the day as on 12:54 IST on the NSE. Dr Reddys Laboratories Ltd is down 25.05% in last one year as compared to a 19.48% spurt in NIFTY and a 9.87% spurt in the Nifty Pharma index. Dr Reddys Laboratories Ltd is up ... Business Standard, 1 week ago
Business Standard

Lupin, Dr Reddy's, Glenmark and Taro see up to 40% decline in the US sales

Requires you to share personal information like date of birth, income, location amongst other fields. This information alongwith your contact information will be shared with the partners associated with this program, who contribute towards subsidizing the ...
 Business Standard1 week ago Plant clearance removes overhang for Dr Reddy's  Business Standard2 months ago
Business Standard

Indian pharma firms renew focus; Dr Reddy's, Cipla eye $100-bn China market

DRL looking to introduce anti-cancer drugs, while Cipla, Wockhardt planning to launch core therapies Aneesh Phadnis & Sohini Das | Mumbai/Ahmedabad Last Updated at February 14, 2018 01:30 IST Dr Reddy’s Laboratories (DRL) is expanding its presence in ...
 Business Standard5 days ago
Money Control

Dr Reddy#39;s may face delays in launch of gSuboxone as Indivior throws new patent challenge

The US unit of Indivior has filed patent lawsuits against generic filers such as Dr Reddy’s, Actavis, Par, Alvogen and Teva for infringement of United States patent number 9,855,221.
 Money Control1 week ago Dr Reddy’s Laboratories gains 2% on Tetrabenazine tablets launch in US market  Money Control1 week ago Dr Reddy's launches generic Tetrabenazine tablets in US  Business Standard2 weeks ago Dr Reddy's in pink of health after launching drug  Business Standard1 month ago
Business Standard

Dr Reddy's recalls 80k bottles of Atorvastatin from US over quality issue

The product is being recalled through three separate letters to the drug regulator Press Trust of India | Hyderabad Last Updated at February 8, 2018 16:11 IST Dr Reddys Laboratories has initiated a voluntary recall of over 80,000 bottles of its drug ...
 Business Standard1 week ago Dr Reddy's recalls 80,000+ bottles of Atorvastatin from US  Business Standard1 week ago Dr Reddy#39;s recalls over 80,000 bottles of Atorvastatin from US  Money Control1 week ago Dr Reddy's recalls single lot of breast cancer drug Docetaxel from US  Business Standard1 month ago
Business Standard

Dr Reddy's Labs acquiring products but not marketing most of them

It's illegal: Modi govt to bar cryptocurrencies from its payments system S 500 erases 2018's gains; US govt plays down Wall St sell-off concerns Doklam was tip of the iceberg! '426 Chinese incursions into India in 2017' Blow for Bitcoin! Banks in UK & US ban ...
 Business Standard1 week ago US court imposes $ 5mn penalty on Dr Reddy's over drug  Business Standard1 month ago Dr Reddy's settles blister package case with US govt for $5 mn  Business Standard2 months ago Dr Reddy's Labs reaches settlement with US Govt  Myiris2 months ago
Business Standard

News digest: Stock markets, IPOs, Tata Motors, Dr Reddy's, and more

BS brings you top stories to keep up with the latest news BS Web Team Last Updated at February 6, 2018 02:11 IST Taxing times for IPOs: LTCG tax prompts issuers to expedite market launch The reintroduction of the long-term capital gains (LTCG) tax has placed ...
 Business Standard1 week ago Dr Reddy#39;s expects US FDA re-audit of Duvvada plant in next 3-6 months  Money Control3 weeks ago Dr Reddy's posts better than expected Q3 numbers but concerns remain  Money Today3 weeks ago Sensex, Nifty trading flat; Sun Pharma, Dr Reddy's, ITC top gainers  Money Today1 month ago
Business Standard

Dr Reddy's falls for fourth straight day on poor Q3 results

The stock was trading 3.4% lower at Rs 2,233, down 13% in past four trading days from Rs 2,562 on January 24, as compared to 0.67% decline in the S&P BSE Sensex. SI Reporter | Mumbai Last Updated at January 31, 2018 12:17 IST Dr Reddy's laboratory Dr ...
 Business Standard2 weeks ago Dr Reddy's Labs Q3 net profit drops 29%; Dalal Street still awaits triggers  Business Standard3 weeks ago Dr Reddy's Q3 consolidated net slips 38.51%, stocks down over 2%  SME Times3 weeks ago Dr Reddy's Q3 net profit falls 38 pc to Rs 303 cr  Business Standard3 weeks ago
Business Standard

Closing Bell: Sensex ends over 60 pts lower ahead of Budget, Nifty holds 11K

Kotak Mahindra Bank, Reliance, and Bharti Infratel gained the most on both indices, while Tata Steel and Dr Reddy’s Laboratories were the top losers.
 Money Control2 weeks ago Dr Reddy's Labs shares extend losses, down 3%  Business Standard1 month ago Sensex falls 59 points to 33,777, Nifty at 10,444 on profit booking; Dr Reddy's, Airtel, Tata Steel top losers  Money Today2 months ago Sensex pares morning gains, falls over nearly 200 pts  Deccan Herald3 days ago
Money Control

Dr Reddy#39;s Labs falls 6% as analysts cut earnings estimates post Q3 nos

Nomura said that the Q3 was below estimates, outlook mostly intact. It also said that approval launches on key products will be key in near term.
 Money Control2 weeks ago Dr Reddy#39;s Labs gains on US FDA nod for Sapropterin Dihydrochloride  Money Control1 month ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less